BioSpace News Archive

Anixa Biosciences, Inc. announced that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Maryland School of Medicine has joined its ongoing prostate cancer Cchek™ study.

Cantel Medical Corp. announced financial results for its fourth quarter ended July 31, 2019.

Collaborative projects will address key questions about how prostate cancer develops and how best to treat it

Concert Pharmaceuticals, Inc. announced that it has named Jeffrey A. Munsie to the position of Chief Legal Officer.

IMV Inc. announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck’s Keytruda® and intermittent low dose cyclophosphamide in patients with advanced and metastatic solid tumors, will be presented during the Immunotherapy of Cancer poster session at the European Society for Medical Oncology 2019 Congress, being held September 27 – October 1, 2019, in Barcelona, Spain.

Omega Therapeutics is unleashing the human genome’s native capacity to regulate genes and cure disease for a new era of genomic medicine

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Data-driven solution identifies gaps in care and enhances proactive patient health management

International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research

AVEO Oncology and EUSA Pharma announced the upcoming presentation of final results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral tivozanib, AVEO’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with intravenous nivolumab, an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma.